Abstract:
The development of novel drugs necessitates meticulous monitoring of various critical aspects to mitigate the risk of cardiovascular complications. Researchers must consider a plethora of targets ranging from the molecular level of ionic channels to the systemic effects of novel compounds. Employing techniques of different scales, such as electrocardiogram (ECG) recordings and field potential recordings of cardiomyocytes with implanted electrodes, presents a challenging yet rewarding approach. This design can yield comprehensive insights into the state of cardiomyocytes within the heart chambers and the heart as a whole. By conducting measurements under conditions where other organs remain intact, researchers can assess the systemic effects of compounds and anticipate or confirm adverse effects during preclinical research. Moreover, this setup provides an opportunity for additional interventions and the simultaneous monitoring of other parameters in the same animal.